PT - JOURNAL ARTICLE AU - Carlson, Nichole E AU - Lippitt, William AU - Ryan, Sarah M AU - Mroz, Margaret AU - Buchalski, Zachary AU - Barkes, Briana AU - Liao, Shu-Yi AU - Maier, Lisa A AU - Fingerlin, Tasha E TI - Radiomic Profiling of Lung CT in a Cohort of Sarcoidosis Cases AID - 10.1101/2022.10.01.22280365 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.01.22280365 4099 - http://medrxiv.org/content/early/2022/10/02/2022.10.01.22280365.short 4100 - http://medrxiv.org/content/early/2022/10/02/2022.10.01.22280365.full AB - Question Addressed High resolution computed tomography (HRCT) of the chest is increasingly used in clinical practice for sarcoidosis. Visual assessment of chest HRCTs in patients with sarcoidosis has high inter- and intra-rater variation. Radiomics offers a reproducible quantitative assessment of HRCT lung parenchyma and could be useful as an additional summary measure of disease. We develop radiomic profiles on HRCT and map them to clinical and patient reported outcomes.Patients and Methods Three-dimensional radiomic features were calculated on chest HRCT for the left and right lung from sarcoidosis cases enrolled in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis study (N=321). Sparse K-means was used to group sarcoidosis cases using their radiomic profiles. Linear regression investigated how pulmonary function tests and patient reported outcomes differed between groups. Resampling approaches were used to validate the robustness of the findings.Results Five groups were identified. The new radiomic-based grouping was associated with Scadding stage (p<0.001), but each radiomic group had patients from all Scadding stages. All pulmonary function testing measures significantly differed between radiomic groups (p<0.001). Radiomic group remained significantly associated with pulmonary function even after adjusting for Scadding stage (p<0.0001). Individual radiomic measures explained 9-18% of the variation in pulmonary function testing. Only two patient reported outcomes (shortness of breath and physical health) differed by radiomic group (p<0.013).Answer to Question Radiomic quantification of sarcoidosis identifies subgroups associated with pulmonary function and patient reported outcomes. These associations provide additional evidence that radiomics may be useful for quantifying new disease phenotypes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by by the National Institutes of Health (R01 HL114587; R01 HL142049; U01 HL112695).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Colorado Multiple Institutional Review Board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available via the process laid out by the GRADS consortium.